title: Yellow fever vaccine: worthy friend or stealthy foe?
abstract: Recognition that the live yellow fever vaccine may rarely be associated with viscerotropic disease (YEL-AVD) has diminished its safety status. However, the vaccine remains the principal tool for limiting the occurrence of yellow fever, making large portions of Africa and South America more habitable. The subject has previously been exhaustively reviewed. Novel concepts in the current report include the description of a systematic method for deciding whom to vaccinate, recommendations for obtaining data helpful in making that decision, and suggestions for additional study. The vaccine is indeed a worthy friend, but its adverse reactions need to be recognized.
authors.affiliation: a Department of Microbiology and Immunology , New York Medical College , Valhalla , NY , USA.|b St. Giles Laboratory of Human Genetics of Infectious Diseases , The Rockefeller University , New York , NY , USA.
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Seligman
authors.affiliation: b St. Giles Laboratory of Human Genetics of Infectious Diseases , The Rockefeller University , New York , NY , USA.|c Howard Hughes Medical Institute , The Rockefeller University , New York , NY , USA.
authors.forename: Jean-Laurent
authors.initials: JL
authors.lastname: Casanova
mesh_terms: D000349:Africa; D006801:Humans; D013020:South America; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D015004:Yellow Fever / Q000517:prevention & control*; D022341:Yellow Fever Vaccine / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*
chemical_list: D014613:Vaccines, Attenuated; D022341:Yellow Fever Vaccine
keywords: YEL-AVD; Yellow fever; vaccine; yellow fever vaccine-associated viscerotropic disease